Advanced targeted therapies dominate treatment pipeline for colorectal cancer.

New analysis from Frost & Sullivan, Item and Pipeline Analysis of the Global Colorectal Cancers Market, finds that advanced targeted therapies are dominating the colorectal malignancy pipeline, accounting for 60 % of the drugs under development. New solutions must compete with well-established products and therefore, need to demonstrate superior profiles with regards to disease-free survival, time to progression, and overall survival rates.In particular, by 2009, HIV individuals were informed they have a one in 25 lifetime risk for developing Kaposi sarcoma, non-Hodgkin lymphoma or lung cancer, the findings showed. However, declines were observed in the rate of Kaposi sarcoma – – simply by 6 % a yr – – and non-Hodgkin lymphoma, which fell by 8 % a year, the study authors reported. No switch was noted for lung tumor, Hodgkin melanoma and lymphoma, the researchers said. ‘This is because the increased risk of developing particular cancers that comes with living longer has been compensated by improvements in care, such as for example reduced smoking, increased knowing of the harmful ramifications of sun publicity, and improved immune function,’ said Silverberg. But anal cancer and liver tumor incidence each went up by 6 % a full year, while colon cancer rose by 5 % annually, the study found.